Core Insights - The top 20 global biopharmaceutical companies saw a 4% increase in combined market capitalisation from $3.7 trillion on June 30, 2025, to $3.8 trillion on September 30, 2025, despite challenges from tariffs and drug pricing pressures [1] Company Performances - UCB experienced the largest market capitalisation growth of 40.9%, reaching $59.8 billion in Q3 2025, driven by the competitive positioning of its drug Bimzelx in hidradenitis suppurativa [2] - Alnylam Pharmaceuticals recorded a 40.6% increase in market capitalisation, attributed to strong sales of its RNAi therapeutic Amvuttra, which saw a 59% quarter-on-quarter increase in global sales to $492 million in Q2 2025 [3] - AbbVie reported a 24.7% rise in market capitalisation, bolstered by its $2.1 billion acquisition of Capstan Therapeutics and plans to invest $195 million in a new manufacturing facility in North Chicago [4] - Johnson & Johnson's market capitalisation grew by 21.5%, supported by a 5.8% sales growth in Q2 and FDA approval of its monoclonal antibody Tremfya for paediatric patients [5]

Core Insights - Johnson & Johnson (NYSE: JNJ) is recognized as one of the top pharmaceutical stocks to buy, demonstrating strong stock performance and growth in its pharmaceuticals and immunology portfolio in 2025 [1]. Regulatory Approvals and Clinical Developments - The company received FDA approval for a subcutaneous induction regimen of Tremfya (guselkumab) for treating adults with ulcerative colitis, marking it as the first and only IL-23 inhibitor with a fully subcutaneous regimen, which showed significant clinical remission in Phase 3 trials [2]. - In Europe, JNJ is advancing nipocalimab, an investigational FcRn blocker for antibody-positive generalized myasthenia gravis, with promising late-stage trial data and pending European Commission approval [3]. - JNJ expanded its oncology portfolio with FDA approval of a new drug delivery system for bladder cancer, providing patients with a potential alternative to surgery [4]. Financial Performance - JNJ's shares have increased by 20% year-to-date, driven by pharmaceutical growth and reduced legal risks compared to previous years, although the company is still dealing with ongoing talc-related litigation [5].

Core Insights - The FDA has approved Johnson & Johnson's Tremfya (guselkumab) as the first IL-23 inhibitor for adults with moderately to severely active Crohn's disease, offering both subcutaneous and intravenous induction options [1] - The approval is based on results from multiple Phase 3 trials involving over 1,300 patients who were either intolerant to or had failed conventional therapies [2] - Tremfya has now received its fourth indication in the U.S., following approvals for plaque psoriasis, psoriatic arthritis, and ulcerative colitis [4] Sales Performance - In 2024, Tremfya generated sales of $3.67 billion, reflecting a 17% year-over-year increase [5] Clinical Studies - The GRAVITI study demonstrated the efficacy of Tremfya SC induction and maintenance therapy compared to placebo [3] - Data from the GALAXI clinical program indicated that Tremfya outperformed Johnson & Johnson's Stelara in all pooled endoscopic endpoints [3]